Literature DB >> 8797652

Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors.

D Ståhlberg1, K Gullberg, L Liljeqvist, G Hellers, R Löfberg.   

Abstract

AIM: This study was undertaken to assess the risk for pouchitis in patients with ulcerative colitis who underwent surgery with colectomy, restorative pelvic pouch, and ileoanal anastomosis and to evaluate possible factors predictive for pouchitis development. PATIENTS AND METHODS: All patients receiving a pelvic pouch because of ulcerative colitis at Huddinge University Hospital between 1980 and 1993 (n = 149; 89 men) were prospectively evaluated for symptoms suggestive of pouchitis. Diagnosis of pouchitis was based on occurrence of certain symptoms in combination with endoscopic findings. Pouchitis was divided into mild and severe, and the time span until the first attack of mild or severe pouchitis was calculated for each patient.
RESULTS: Median follow-up time was 54 (5-152) months. The absolute cumulative risk of developing mild pouchitis was 21, 26, and 39 percent at 6, 12, and 48 months, respectively. The corresponding cumulative risk of developing severe pouchitis was 9, 11, and 14 percent, respectively. Risk for both groups together was 51 percent at 48 months. The occurrence of pouchitis, calculated at six-month intervals after closure of the loop ileostomy, was highest (23.1 percent) during the first six months. Incidence during the next six-month period was 11.4 percent and then only 3.1 percent thereafter. Thirty-two patients (21.5 percent) had chronic continuous symptoms requiring long-term metronidazole treatment, and 14 (9.4 percent) of those had chronic severe pouchitis. In two patients, removal of the pouch and permanent ileostomy became necessary. Extracolonic manifestations and early onset of ulcerative colitis were predictive factors for developing pouchitis. Former smoking seemed to be a protective factor.
CONCLUSION: The risk for pouchitis was highest during the initial six-month period. Cumulative risk leveled off after two years but was substantial (51 percent) at four years. Less than 10 percent of patients had severe, chronic pouchitis, and only two patients (1.3 percent) had their pouches removed.

Entities:  

Mesh:

Year:  1996        PMID: 8797652     DOI: 10.1007/bf02054692

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  50 in total

1.  Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis.

Authors:  T Kühbacher; P Gionchetti; J Hampe; U Helwig; P Rosenstiel; M Campieri; H J Buhr; S Schreiber
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

Review 2.  Ulcerative colitis.

Authors:  S Ghosh; A Shand; A Ferguson
Journal:  BMJ       Date:  2000-04-22

3.  Antagonist: Early surgical intervention in ulcerative colitis.

Authors:  M A Kamm
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

4.  Tissue-engineered large intestine resembles native colon with appropriate in vitro physiology and architecture.

Authors:  Tracy C Grikscheit; Erin R Ochoa; Anthony Ramsanahie; Eben Alsberg; David Mooney; Edward E Whang; Joseph P Vacanti
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

5.  The bacterial pathogenesis and treatment of pouchitis.

Authors:  S D McLaughlin; S K Clark; P P Tekkis; R J Nicholls; P J Ciclitira
Journal:  Therap Adv Gastroenterol       Date:  2010-11       Impact factor: 4.409

6.  Persistence of high CD40 and CD40L expression after restorative proctocolectomy for ulcerative colitis.

Authors:  Lino Polese; Imerio Angriman; De Franchis Giuseppe; Attilio Cecchetto; Giacomo-C Sturniolo; D'Inca Renata; Marco Scarpa; Cesare Ruffolo; Lorenzo Norberto; Mauro Frego; Davide-F D'Amico
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

7.  Diagnosis and treatment of ileal pouch diseases in patients with underlying ulcerative colitis.

Authors:  Bo Shen; Bret Lashner
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

8.  Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis: effect on quality of life.

Authors:  Matthias Turina; Connie J Pennington; Jennifer Kimberling; Arnold J Stromberg; Robert E Petras; Susan Galandiuk
Journal:  J Gastrointest Surg       Date:  2006-04       Impact factor: 3.452

9.  Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.

Authors:  T Mimura; F Rizzello; U Helwig; G Poggioli; S Schreiber; I C Talbot; R J Nicholls; P Gionchetti; M Campieri; M A Kamm
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.

Authors:  P R Fleshner; E A Vasiliauskas; L Y Kam; N E Fleshner; J Gaiennie; M T Abreu-Martin; S R Targan
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.